These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27488872)

  • 1. Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.
    Huang J; Zhang F; Jiang L; Hu G; Sun W; Zhang C; Ding X
    Cancer Res Treat; 2017 Apr; 49(2):358-373. PubMed ID: 27488872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
    J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
    Tang C; Zhu J; Yuan F; Yang J; Cai X; Ma C
    Mol Neurobiol; 2021 Dec; 58(12):6170-6185. PubMed ID: 34463926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
    BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma.
    Gruszka A; Kunert-Radek J; Pawlikowski M
    Folia Histochem Cytobiol; 2004; 42(1):35-9. PubMed ID: 15046398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
    Zhang SL; Tang HB; Hu JT; Zang ZL; Ding X; Li S; Yang H
    Biomed Pharmacother; 2019 Mar; 111():638-648. PubMed ID: 30611988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
    Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
    Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
    Li Q; Su Z; Liu J; Cai L; Lu J; Lin S; Xiong Z; Li W; Zheng W; Wu J; Zhuge Q; Wu Z
    Mol Cell Endocrinol; 2014 Jan; 382(1):377-384. PubMed ID: 24184771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
    Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
    J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas.
    Geng X; Ma L; Li Z; Li Z; Li J; Li M; Wang Q; Chen Z; Sun Q
    World Neurosurg; 2017 Apr; 100():407-416. PubMed ID: 28137551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.
    Miller M; Chen S; Woodliff J; Kansra S
    Endocrinology; 2008 Aug; 149(8):4158-67. PubMed ID: 18450960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells.
    Kanasaki H; Fukunaga K; Takahashi K; Miyazaki K; Miyamoto E
    Biol Reprod; 2000 Jun; 62(6):1486-94. PubMed ID: 10819748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
    Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
    Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
    Caccavelli L; Feron F; Morange I; Rouer E; Benarous R; Dewailly D; Jaquet P; Kordon C; Enjalbert A
    Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors.
    Musat M; Korbonits M; Pyle M; Gueorguiev M; Kola B; Morris DG; Powell M; Dumitrache C; Poiana C; Grossman AB
    Pituitary; 2002; 5(4):235-42. PubMed ID: 14558671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
    Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
    Shimazu S; Shimatsu A; Yamada S; Inoshita N; Nagamura Y; Usui T; Tsukada T
    Eur J Endocrinol; 2012 Mar; 166(3):383-90. PubMed ID: 22127489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
    Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
    Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis.
    Jiang YN; Li YH; Ke MW; Tseng TY; Tang YB; Huang MC; Cheng WT; Ju YT
    Cancer Cell Int; 2007 Mar; 7():1. PubMed ID: 17331262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.